BTBC - B2B Stores.com Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : BTBC - B2B Stores.com

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: westpacific who started this subject	3/1/2001 12:16:27 AM
From: Glenn Petersen	Read Replies (1) of 26

The BTBC shareholder meeting is scheduled for Monday, March 5, at 10:00 a.m. At that meeting, the shareholders of BTBC should approve the reverse merger of Ivax Diagnostics into BTBC. Ivax, the parent of Ivax Diagnostics, will receive 20 million shares of BTBC. In the event that the merger is not approved, BTBC will liquidate the company and distribute the proceeds to its shareholders. From the proxy materials: "As we have discontinued our business operations, we will most likely liquidate if the merger is not approved. If the merger is not approved and we do liquidate, we will have to pay all expenses we incurred in connection with the transaction, a termination fee to IVAX in the amount of $1.0 million, and the expenses of the liquidation. After giving effect to the payment of such expenses and assuming we would liquidate shortly after the special meeting, we estimate that you would receive approximately $2.59 for each share of our common stock you hold at the time of our liquidation. The definitive proxy statement can be found at: sec.gov

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next